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OBJECTIVE
Approximately 18 million people in the U.S. have coexisting type 2 diabetes and
nonalcoholic fatty liver disease (NAFLD). It is not known who among these
patients has nonalcoholic steatohepatitis (NASH) with advanced fibrosis. There-
fore, we aimed to determine factors that are associated with both NASH and
advanced fibrosis in patients with diabetes and NAFLD in order to identify who
should be prioritized for referral to a hepatologist for further diagnostic evalua-
tion and treatment.
RESEARCH DESIGN AND METHODS
This study was derived from the NASH Clinical Research Network studies and
included 1,249 patients with biopsy-proven NAFLD (including a model develop-
ment cohort of 346 patients and an independent validation cohort of 100 patients
with type 2 diabetes as defined by the American Diabetes Association criteria).
Outcome measures were presence of NASH or advanced fibrosis (stage 3 or 4)
using cross-validated, by jackknife method, multivariable-adjusted area under the
receiver operating characteristic curve (AUROC) and 95% CI.
RESULTS
Themean6 SD age and BMI of patients with diabetes and NAFLD was 52.56 10.3
years and 35.86 6.8 kg/m2, respectively. The prevalence of NASH and advanced
fibrosis was 69.2% and 41.0%, respectively. The model for NASH included white
race, BMI, waist, alanine aminotransferase (ALT), Aspartate aminotransferase
(AST), albumin, HbA1c, HOMA of insulin resistance, and ferritin with an AUROC
of 0.80 (95% CI 0.75–0.84, P = 0.007). The specificity, sensitivity, negative pre-
dictive values (NPVs), and positive predictive values (PPVs) were 90.0%, 56.8%,
47.7%, and 93.2%, respectively, and the model correctly classified 67% of patients
as having NASH. Themodel for predicting advanced fibrosis included age, Hispanic
ethnicity, BMI, waist-to-hip ratio, hypertension, ALT-to-AST ratio, alkaline phos-
phatase, isolated abnormal alkaline phosphatase, bilirubin (total and direct),
globulin, albumin, serum insulin, hematocrit, international normalized ratio,
and platelet count with an AUROC of 0.80 (95% CI 0.76–0.85, P < 0.001). The
specificity, sensitivity, NPV, and PPV were 90.0%, 57%, 75.1%, and 80.2%, respec-
tively, and the model correctly classified 76.6% of patients as having advanced
fibrosis. Results remained consistent for bothmodels in the validation cohort. The
proposed model performed better than the NAFLD fibrosis score in detecting
advanced fibrosis.
CONCLUSIONS
Routinely available clinical variables can be used to quantify the likelihood of
NASH or advanced fibrosis in adult diabetic patients with NAFLD. The clinical
models presented can be used to guide clinical decision making about referrals
of patients with diabetes and NAFLD to hepatologists.
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Nonalcoholic fatty liver disease (NAFLD)
is the most common cause of chronic
liver disease in the U.S. (1–3). Approxi-
mately 10–22% of patients with NAFLD
have the progressive subtype of NAFLD
termed nonalcoholic steatohepatitis
(NASH), which can result in cirrhosis, he-
patocellular carcinoma, and liver-
related mortality (4–9). Type 2 diabetes
is considered a major risk factor for ad-
vanced liver disease in patients with
NAFLD (10–12).
It is estimated that ;25.8 million
Americans are afflicted with diabetes
(13–15). Several studies have shown
that prevalence of NAFLD in patients
with diabetes is increased compared
with those without diabetes (16–21). Al-
though the exact prevalence of NAFLD in
patients with diabetes is not known,
previous studies suggest that it ranges
between 49.6 and 74% (17,21–25).
Therefore, it can be estimated that
;13–18 million people in the U.S. have
coexisting diabetes and NAFLD. This
study aimed to address the clinical risk
stratification that may be applied to this
group of patients.
The presence of diabetes has consis-
tently been shown to be a key predictor
of NASH and advanced fibrosis in NAFLD
(11,26,27). Several experts have recom-
mended liver biopsy in select NAFLD pa-
tients with diabetes (28–32). In this era of
accountable health care and increasing
cost constraints, it is not feasible to rec-
ommend liver biopsy in all patients who
have diabetes and NAFLD. For that rea-
son, we aimed to determine the most re-
liable factors that are associated with
NASH or advanced fibrosis in patients
with diabetes andNAFLD in order to iden-
tify patients who should be prioritized
for a liver biopsy and/or referred to a hep-
atologist for further evaluation.
RESEARCH DESIGN AND METHODS
Study Design, Setting, and
Participants
This is a cross-sectional analysis of pro-
spectively evaluated adult patients with
biopsy-proven NAFLD who were enrolled
into theNAFLDDatabase Study, a prospec-
tive cohort study, conducted by the Na-
tional Institute of Diabetes and Digestive
and Kidney Diseases (NIDDK)-sponsored
Nonalcoholic Steatohepatitis Clinical Re-
search Network (NASH CRN) (33,34). The
NASH CRN studies enrolled 1,266 patients
with biopsy-proven NAFLD; patients
enrolled through June 2012 were in-
cluded in this analysis (33,34). Partici-
pants were enrolled by one of the eight
participating medical centers in the U.S.:
University of California, San Diego (La
Jolla, CA); Duke University (Durham,
NC); Case Western Reserve University/
Cleveland Clinic Foundation (Cleveland,
OH); Indiana University (Indianapolis, IN);
Saint Louis University (St. Louis, MO); Uni-
versity of California, San Francisco (San
Francisco, CA); University of Washington/
Virginia Mason Medical Center (Seattle,
WA); and Virginia Commonwealth Univer-
sity (Richmond, VA). All participants pro-
vided written informed consent prior to
data collection. The subjects’ demographic
characteristics, anthropomorphic meas-
urements, alcohol consumption, medical
history, medication use, clinical tests, and
liver biopsy results were prospectively col-
lected; thedetailed inclusionandexclusion
criteria have previously been described
(34,35). Liver biopsies were obtained dur-
ing the study period as clinically indicated.
All protocols, consent forms, and manuals
of operations were reviewed by a data
safety-monitoring board established by
the NIDDK for the NASH CRN and ap-
proved by the institutional review board
for each site.
NAFLD Diagnosis
Participants had to meet specific criteria
regarding the diagnosis of NAFLD in or-
der to be enrolled in this study as pre-
viously published (34). Patients with
alcohol consumption of .140 g/week
if male or .70 g/week if female in the
2 years prior to screening were ex-
cluded. Patients with other etiologies
of chronic liver disease were also ex-
cluded. For the purpose of enrollment
into the observational NAFLD Database
Study, the diagnosis of NAFLDwas based
on the histological diagnosis of NAFLD
or cryptogenic cirrhosis or on imaging
studies (34). For this study, only patients
with liver biopsy data available within 6
months of the clinic data were included.
Description of Liver Histology
Assessment
Liver biopsy slides were stained with he-
matoxylin-eosin,Masson trichrome, and
Perls iron stain. The NASH CRN Pathol-
ogy Committee reviewed and scored the
slides without any knowledge of pa-
tient’s previous diagnosis, clinical infor-
mation, or laboratory values or the
study for which the biopsy was being
evaluated (36,37). The committee used
Brunt modified classification to stage fi-
brosis: 0 = no fibrosis; 1a = mild, zone 3
perisinusoidal fibrosis; 1b = moderate,
zone 3 perisinusoidal fibrosis; 1c = por-
tal/periportal only fibrosis; 2 = zone 3
perisinusoidal and periportal fibrosis;
3 = bridging fibrosis; and 4 = cirrhosis
(36,38,39). Advanced fibrosis was de-
fined as stages 3–4. Patients were clas-
sified as having no NASH, possible/
borderline NASH, or definite NASH as
previously described (36). For the pur-
poses of this analysis, patients with pos-
sible/borderline NASH were grouped
with patients with no NASH.
Outcome Measures
The primary outcome measure was pres-
ence of definite NASH as determined by
the Pathology Committee’s review of the
liver biopsy (36). NASHwas defined as pres-
ence of steatosis predominantly in zone 3,
with varying degrees of lobular inflamma-
tion, and classic ballooning degeneration
with or without presence of Mallory-Denk
bodies and/or peri-sinusoidal fibrosis.
The secondary outcome measure was
presence of advanced fibrosis on liver bi-
opsy defined as presence of stage 3 or 4
fibrosis on the NASH CRN histologic scor-
ing system (36).
Covariates
All data analyzed in this study were ob-
tainedwithin 6months of the liver biopsy.
The following variableswere included: de-
mographic features (age at enrollment
[years], sex, race [white or other], ethnic-
ity [Hispanic/Latino]), clinical data (waist
circumference, waist-to-hip ratio, BMI
[kg/m2], hypertension), laboratory mea-
sures (serum alanine [ALT] and aspartate
[AST] aminotransferase, g-glutamyl trans-
peptidase [GGT], albumin, international
normalized ratio [INR], bilirubin, triglycer-
ide, HDL, fasting serumglucose and insulin
levels, and complete blood count), and
presence of type 2 diabetes.
Diabetes status was based upon previ-
ous history of diabetes, use of medica-
tions to treat diabetes, and/or fasting
plasma glucose$126 mg/dL or a 2-h glu-
cose $200 mg/dL during an oral glucose
tolerance test or HbA1c$6.5%, consistent
with the American Diabetes Association
criteria for the diagnosis of diabetes (40).
Statistical Analyses
Group comparisons used the two-tailed
t test for continuous dependent variables
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and Fisher exact test for categorical
variables. Multivariate logistic regres-
sion models were used to analyze the
diagnostic power of clinical and bio-
chemical characteristics to predict
the presence of NASH and of advanced
fibrosis. We selected the predictor vari-
ables for the clinical prediction models
for NASH and for advanced fibrosis using
stepwise logistic regression models
derived from a large candidate set of
clinical variables by application of the
Akaike information criterion (AIC) to se-
lect each predictor. Predictors with
higher information content were se-
lected in the models for the probabilities
of NASH. Since AIC is defined as 22log
likelihood + 2p, were p = number of pre-
dictors in a model, models with more
predictors are “penalized” by the 2p fac-
tor in the AIC. This means that a new
predictor must improve the information
in the model (AIC) more than enough to
overcome the “penalty” assigned for
adding a new predictor to the model.
This approach results in predictors se-
lected for models on the basis of a stan-
dard measure of information content
and avoids the difficult multiplicity of
comparison problems present when pre-
dictor selection uses P values.
We calculated the cross-validated
areas under the receiver operating char-
acteristic curves (AUROCs), positive pre-
dictive value (PPV), negative predictive
value (NPV), the percent correctly clas-
sified, sensitivity, and specificity to mea-
sure the diagnostic test characteristics
of each model. Next, we calculated low-
probability cut points for “not NASH” and
“not advanced fibrosis” based on the NPV
of 90% (or the largest NPV defined) and
high probability cut points for “NASH”
and “advanced fibrosis” based on the PPV
of 90% (or largest PPV defined). The “gray
zone” is defined as the probability scores
that fall in between the low- and high-
probability cutpoints.Using thesecutpoints,
we calculated the number of correctly
and incorrectly classified biopsies and the
potential for biopsies spared, aswell as the
number of patient biopsies falling in be-
tween the lower andhigher cut points (34).
Independent Assessment of
Model Performance: AUROC
Using Jackknifing and AUROC
in Validation Cohort
We used a statistical jackknife pro-
cedure to obtain an internal but
independently validated (cross-validated)
and thus more realistic estimate of an
AUROC. If n = number of patients, the
cross-validated AUROC is obtained by
fitting a total of n different models and
obtaining n independently predicted
probabilities (scores) of NASH or ad-
vanced fibrosis, each with a sample size
of n 2 1 obtained by deleting one pa-
tient at a time until the n independent
scores have been obtained. These inde-
pendent scores are used to predict each
of the n outcomes and calculate the
jackknifed AUROC (41). The jackknife
procedure results in independent, and
thus more valid, AUROC estimates, since
its predictions are of patient results using
models fit to data external to the patient
being predicted. While a jackknifed
AUROC is superior to an ordinary biased
AUROC by virtue of predicting outcomes
using models derived from these same
outcomes, clinical prediction models, to
be useful, must be validated in a popu-
lation that is external to the population
used to develop the model. We approx-
imated this using our model for predict-
ing advanced fibrosis in future NASH CRN
patients as read by a pathologist serving
each clinic rather than the central con-
sensus reading at the histology reading
center for the NASH CRN. The model for
advanced fibrosis was externally vali-
dated using a cohort of NASH CRN
patients not included in the primary
analysis. This validation cohort consisted
of 100 patients from the same studies
and time period as used for the model
development based upon central review
of cases. Finally, we compared our clini-
cal model for advanced fibrosis with a
published model for predicting ad-
vanced fibrosis by applying this model
to our data and comparing the cross-
validated AUROCs, PPV, NPV, specificity,
and sensitivity.
P values were considered statistically
significant if P, 0.05. All analyses were
conducted using SAS 9.2 (SAS Institute,
Cary, NC) and Stata 13.1 (StataCorp, Col-
lege Station, TX).
RESULTS
Baseline Data
This study included 1,249 patients with
biopsy-proven NAFLD; 435 (34.8%) of
these patients had diabetes. The aver-
age age and BMI of these patients
with diabetes and NAFLD was 52.4 6
10.3 years and 35.8 6 6.6 kg/m2,
respectively. Among the 346 patients
with diabetes and NAFLD, the preva-
lence of NASH and advanced fibrosis
was 69.2% and 41.0% (Table 1). Detailed
baseline characteristics of the patients
with diabetes are shown in Table 1.
Predictors of Presence of NASH in
Patients With Diabetes
Univariate Analysis
Table 1 describes the baseline charac-
teristics of patients with diabetes clas-
sified by the presence or absence of
definite NASH. In univariate models,
factors associated with presence of
NASH on histology included elevated
AST or ALT (P , 0.0001), serum insulin
(P = 0.001), HbA1c (P = 0.006), and
HOMA of insulin resistance (HOMA-IR)
(P = 0.002).
Multivariable-Adjusted Analyses
A multivariable-adjusted model (clinical
model) was developed using AIC criteria.
In the clinical model (Table 2), the factors
associated with presence of NASH on his-
tology included white race, BMI, waist
(measured in centimeters), ALT, AST, al-
bumin, HbA1c, HOMA-IR, and ferritin
with a cross-validated AUROC of 0.80
(95% CI 0.75–0.84, P value = 0.007). The
specificity, sensitivity, NPVs, and PPVs
were 90.0%, 56.8%, 47.7%, and 93.2%,
respectively, and this model correctly
classified 67% of patients as having
NASH (Table 2).
Predictors of Advanced Fibrosis
Univariate Analysis
Table 1 describes the baseline character-
istics of patients with diabetes stratified
by the presence of advanced fibrosis. In
univariate models, the factors associated
with advanced fibrosis included age (P,
0.0001), hypertension (P = 0.006), ele-
vated AST (P = 0.02), AST-to-ALT ratio
(P , 0.0001), GGT (P = 0.0006), globulin
(P = 0.01), direct bilirubin (P = 0.01), se-
rum insulin (P = 0.002), HOMA-IR (P =
0.003), LDL (P = 0.05), white blood cell
count (P = 0.002), INR (P = 0.0003), and
platelet count (P , 0.0001).
Multivariable-Adjusted Analysis
A multivariable-adjusted model (clini-
cal model) was developed using AIC
criteria. In the clinical model (Table
3), the factors associated with ad-
vanced fibrosis included age, Hispanic
ethnicity, BMI, waist-to-hip ratio,
hypertension, AST-to-ALT ratio, alkaline
phosphatase, isolated abnormal alkaline
care.diabetesjournals.org Bazick and Associates 1349
phosphatase, globulin, albumin, bilirubin
(total and direct), serum insulin, he-
matocrit, INR, and platelet count
with a cross-validated AUROC of 0.80
(95% CI 0.76–0.85). The specificity,
sensitivity, NPV, and PPV were 90%,
57%, 75.1%, and 80.2%, respectively,
and this model correctly classified
76.6% of patients as having advanced
fibrosis (Table 3).
Clinical Application of Proposed
Models for NASH and for Advanced
Fibrosis
Table 4 provides the probability of pres-
ence of NASH and advanced fibrosis at
Table 1—Adult patients with diabetes and NAFLD: baseline characteristics by the presence of NASH and presence of advanced
fibrosis
Characteristics
Presence of NASH
P* (NASH
vs. not NASH)
Presence of advanced fibrosis
No
(n = 105)
Yes
(n = 241)
No: none,
mild, or
moderate
(n = 204)
Yes:
bridging or
cirrhosis
(n = 142)
P* (advanced
fibrosis vs. not
advanced fibrosis)
Demographics
Male, n (%) 38 (36.2) 68 (28.2) 0.16 62 (30.4) 44 (31.0) 0.91
Age (years), mean 6 SD 51.7 6 10.0 52.8 6 10.4 0.37 50.3 6 11.2 55.7 6 7.9 ,0.0001
White, n (%) 83 (79.0) 200 (83.0) 0.45 163 (79.9) 120 (84.5) 0.32
Hispanic, n (%) 8 (7.6) 23 (9.5) 0.68 21 (10.3) 10 (7.0) 0.34
Clinical, n (%)
Hypertension 26 (24.8) 98 (40.7) 0.005 61 (29.9) 63 (44.4) 0.006
Metabolic syndrome§ 76 (72.4) 206 (85.5) 0.006 165 (80.9) 117 (82.4) 0.78
Acanthosis nigricans§§ 14 (13.3) 41 (17.0) 0.43 34 (16.7) 21 (14.8) 0.66
Anthropometric, mean 6 SD
BMI (kg/m2) 35.1 6 6.9 36.2 6 6.8 0.17 35.5 6 6.6 36.4 6 7.1 0.24
Waist (cm) 112.3 6 14.8 113.4 6 14.7 0.49 112.4 6 14.0 114.1 6 15.7 0.28
Waist-to-hip ratio 0.95 6 0.08 0.95 6 0.08 0.72 0.95 6 0.07 0.95 6 0.08 0.38
Laboratory measures, mean 6 SD
AST (units/L) 36.4 6 17.0 65.6 6 46.8 ,0.0001 52.6 6 45.2 62.8 6 37.2 0.02
ALT (units/L) 51.5 6 33.5 80.9 6 59.8 ,0.0001 71.9 6 59.6 72.0 6 47.3 0.98
AST-to-ALT ratio 0.82 6 0.37 0.88 6 0.32 0.12 0.78 6 0.28 0.98 6 0.389 ,0.0001
Alkaline phosphatase (units/L) 86.9 6 35.4 95.2 6 41.3 0.06 86.8 6 31.4 101.0 6 49.2 0.002
Isolated abnormal alkaline
phosphatase§§§ 9 (8.6) 6 (2.5) 0.02 8 (3.9) 7 (4.9) 0.79
GGT (units/L) 70.4 6 94.2 98.7 6 124.0 0.02 70.7 6 86.7 118.0 6 144.8 0.0006
Globulin (g/dL) 3.06 6 0.52 3.13 6 0.53 0.25 3.05 6 0.52 3.19 6 0.54 0.01
Albumin (g/dL) 4.15 6 0.41 4.21 6 0.43 0.22 4.26 6 0.42 4.16 6 0.43 0.18
Total bilirubin (mg/dL) 0.71 6 0.43 0.67 6 0.31 0.42 0.66 6 0.36 0.71 6 0.34 0.17
Direct bilirubin (mg/dL) 0.15 6 0.11 0.15 6 0.08 0.84 0.14 6 0.08 0.16 6 0.10 0.01
INR 1.02 6 0.20 1.05 6 0.22 0.28 1.00 6 0.19 1.09 6 0.23 0.0003
Hematocrit (%) 40.5 6 3.9 41.1 6 3.9 0.74 41.2 6 3.8 40.4 6 4.0 0.06
White blood cells (1,000/mm3) 7.18 6 2.3 7.23 6 2.1 0.87 7.51 6 2.1 6.79 6 2.1 0.002
Platelet count (1,000/mm3) 240.1 6 80.7 223.9 6 71.9 0.08 252.8 6 71.1 194.3 6 66.5 ,0.0001
Total cholesterol (mg/dL) 178.2 6 41.1 192.1 6 44.3 0.005 191.1 6 44.4 183.3 6 42.4 0.10
HDL cholesterol (mg/dL) 41.5 6 11.2 41.7 6 10.7 0.88 41.2 6 10.3 42.2 6 11.6 0.37
LDL cholesterol (mg/dL) 105.8 6 34.6 114.2 6 36.5 0.04 114.8 6 36.5 107.2 6 35.2 0.05
Triglycerides (mg/dL) 164.9 6 76.7 190.0 6 93.3 0.01 187.4 6 88.0 175.2 6 90.7 0.21
HbA1c (%) 6.8 6 1.2 7.4 6 1.3 0.006 7.14 6 1.31 7.25 6 1.28 0.93
HbA1c (mmol/L) 50.9 6 13.2 56.9 6 14.2 0.0003 54.6 6 14.3 55.7 6 14.0 0.45
Serum glucose (mg/dL) 124.7 6 38.2 138.6 6 52.3 0.006 132.3 6 48.1 137.4 6 49.9 0.35
Serum insulin (mU/mL) 23.7 6 15.9 32.5 6 34.4 0.001 25.3 6 23.1 36.4 6 37.4 0.002
HOMA-IR (mg/dL3 mU/mL/405) 7.2 6 5.0 11.4 6 13.7 0.002 8.42 6 9.0 12.6 6 14.8 0.003
Ferritin (ng/mL) 166.3 6 169.2 249.1 6 322.9 0.002 212.6 6 269.7 240.2 6 311.5 0.39
Histology, n (%)
Steatosis $34% 48 (45.7) 153 (63.5) 0.003 131 (64.2) 70 (49.3) 0.008
Lobular inflammation $grade 2 29 (27.6) 143 (59.3) ,0.0001 100 (49.0) 72 (50.7) 0.50
Ballooning: any 25 (23.8) 241 (100.0) ,0.0001 135 (66.2) 131 (92.2) ,0.0001
Fibrosis stage: bridging or
cirrhosis 21 (20.0) 121 (50.2) ,0.0001 102 (50.0) 84 (59.2) 0.03
NAS, mean 6 SD 3.06 6 1.12 5.39 6 1.32 ,0.001 4.52 6 1.70 4.92 6 1.56 0.09
NAS $5, n (%) 11 (10.5) 175 (72.6) ,0.0001 120 (58.8) 121 (85.2) ,0.0001
Note: patients are from the NASH CRN cohort studies (Database and DB2) enrolled between September 2004 and December 2012. Diagnosis of
definite NASH and advanced fibrosis was determined by central review of liver biopsies by the NASH CRN Pathology Committee. NAS, NAFLD activity
score. *P values determined from Fisher exact test for categorical variables or from t test for continuous variables. §National Cholesterol Education
Program definition. §§0 = absent, 1 = present on close inspection, 2 = mild, 3 = moderate, 4 = severe. §§§Defined as alkaline phosphatase$1 upper
limit of normal (ULN), AST , 1 ULN, and ALT , 1 ULN according to local reference ranges.
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various cut points. It also shows the cut
points that could be used in clinical prac-
tice to determine when to consider a bi-
opsy for the diagnosis of NASH; a model
parameter of.0.75would result in a PPV
of 90% for the presence of NASH. Simi-
larly, for advanced fibrosis, a cut point
.0.85 would result in a PPV of 89.5%
for advanced fibrosis.
Internal Cross-Validation and External
Validation
Internal cross-validation was done and
is shown in Table 3 using jackknife pro-
cedures (as explained in RESEARCH DESIGN
AND METHODS). Using an independent val-
idation cohort of 100 patients recruited
from the NASH CRN sites as part of the
same studies, we showed that the re-
sults remained consistently robust with
AUROC for NASH and advanced fibrosis
in the validation cohort of 0.83 (95% CI
0.75–0.92) and 0.84 (0.76–0.92), respec-
tively (as shown in Table 5).
Comparison Between the Proposed
Diabetes-Specific Model and NAFLD
Fibrosis Score
Finally, we compared the diagnostic ac-
curacy of the current model (developed
specifically for patients with diabetes)
with the NAFLD Fibrosis Score (as shown
in Supplementary Table 1). The models
developed for the diabetic population
were significantly more accurate than
the previously published NAFLD Fibrosis
Score applied to this population for the
diagnosis of advanced fibrosis, with a
cross-validated AUROC of 0.80 vs. 0.76
(P , 0.05).
CONCLUSIONS
Main Findings
With a large, well-characterized co-
hort of patients with biopsy-proven
NAFLD and diabetes, we demonstrate
that routinely available clinical and
biochemical factors can be used to ac-
curately determine the likelihood of
NASH (AUROC 0.80, P = 0.007) and ad-
vanced fibrosis (AUROC 0.80, P ,
0.001) in patients with diabetes and
NAFLD. These data can guide clini-
cians regarding when to refer patients
with diabetes who have NAFLD for a
liver biopsy. The application of these
prediction models accurately classi-
fied 67% of our study set with NASH
and 77% with advanced fibrosis. The
models are clinically stringent and
weighted to having high PPVs with
the trade-off of lower NPVs. Thus,
clinical judgment and further testing,
including liver biopsies, may still be
needed in patients determined not
to be at high risk for NASH or ad-
vanced fibrosis using these models
but would correctly classify three-
quarters of patients with advanced
fibrosis.
Prior studies have used similar clinical
and laboratory measures to identify pa-
tients with NAFLD to predict the pres-
ence or absence of advanced fibrosis in
NAFLD patients. One example is the
Fatty Liver Index, which uses triglyceride
level and waist circumference to predict
NAFLD (42,43). Other studies of NAFLD
patients have demonstrated that the
presence of metabolic syndrome and
hypertriglyceridemia, higher AST-to-
ALT ratio, and lower platelet count are
associatedwithmore advanced liver dis-
ease (34,44). Clinical prediction rules
have also been created to identify
NAFLD patients with and without ad-
vanced fibrosis. One example is the
well-validated NAFLD fibrosis score,
which consists of age, BMI, impaired
fasting glucose or diabetes, AST-to-ALT
ratio, platelet count, and albumin
(45,46). Our model performed better
than the NAFLD fibrosis score. Unlike
prior studies, the current model pro-
posed in this study focuses on patients
with diabetes, a population known to
have higher risk of NASH, advanced fi-
brosis, and mortality (10,26,47–50). The
models developed in this study can thus
help to identify patients with diabetes at
high risk for the presence of NASH or
advanced fibrosis and help guide clini-
cians when to refer patients with diabe-
tes for a liver biopsy and appropriate
management. Future studies combining
Table 2—Clinical model for NASH in adult patients with diabetes and NAFLD
Characteristics (n = 346)
Clinical model*
OR 95% CI P
Demographics
White versus nonwhite 1.76 0.86–3.60 0.12
Obesity measures
BMI (kg/m2) 1.11 1.03–1.20 0.006
Waist (cm) 0.97 0.93–0.999 0.04
Laboratory measures
AST (units/L) 1.07 1.04–1.10 ,0.001
ALT (units/L) 0.98 0.97–0.998 0.03
Albumin (g/dL) 2.03 0.96–4.30 0.06
HbA1c (%) 1.27 0.93–1.64 0.06
HOMA-IR (mg/dL 3 mU/mL/405) 1.06 1.01–1.09 0.18
Ferritin (ng/mL) 1.001 1.000–1.003 0.04
Model performance
Cross-validated AUROC 0.80 0.75–0.84
PPV 93.2%
NPV 47.7%
Correctly classified 67.0%
Sensitivity 56.8%
Specificity (fixed at 90%) 90.0%
AIC 342.2
Population prevalence of NASH 70%
Probability cutoff for NASH† $0.77
Clinical model for P (probability of NASH). Coefficients and SEs shown as b(SE): log(P/1 2 P) =
27.00(2.47) + 0.106(0.039) 3 BMI (kg/m2) – 0.035(0.017) 3 waist (cm) + 0.068(0.012) 3 AST
(units/L) – 0.016(0.007)3ALT (units/L) + 0.71(0.38)3 albumin (g/dL) + 0.24(0.13)3HbA1c (%) +
0.057(0.024) 3 HOMA-IR (mg/dL 3 mU/mL/405) + 0.0014(0.0007) 3 ferritin (ng/dL) + 0.57
(0.36) if white. PPV: probability that the disease is present when the test is positive; NPV:
probability that the disease is not present when the test is negative. *Logistic regression model
variables selected from candidate set of baseline variables using AIC with backward selection to
select the model with the highest information from a large candidate set of baseline variables to
identify the predictors of NASH in adult patients with diabetes with NAFLD: age, sex, white race,
Hispanic ethnicity, hypertension, metabolic syndrome, abnormal alkaline phosphatase, BMI,
waist (cm), waist-to-hip ratio, AST, ALT, AST-to-ALT ratio, alkaline phosphatase, albumin, direct
bilirubin, total bilirubin, white blood cell count, platelets, GGT, total cholesterol, HDL, LDL,
triglycerides, ferritin, INR, serum glucose, serum insulin, globulin, hematocrit, HbA1c, and
HOMA-IR. †Classify as NASH if themodel probability of NASH is$0.77. This cutoff was chosen to
give a specificity of 0.90.
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the clinical prediction rules with other
noninvasive imaging methods (51)
need to be performed to further im-
prove the diagnostic accuracy.
Strengths and Limitations
The NASH CRN cohort is a multiethnic
and multicenter study including eight
sites across the U.S. This ethnic and geo-
graphic variation is a strength that may
allow the results to be applied to other
NAFLD patients in the U.S. Additionally,
the NASH CRN cohort includes prospec-
tive cohort data. The histology was also
subject to blinded analysis by a commit-
tee of expert pathologists who used the
accepted and validated NASH CRN his-
tology scoring system. A series of vali-
dation procedures were used to confirm
the reproducibility of findings. We per-
formed jackknife internal cross-validation
of AUROC, as it is superior to an ordinary
biased AUROC. In order for themodels to
be generalizable, they must be validated
in a population that is external to the
population used to develop the model.
We approximated this using our model
for predicting advanced fibrosis in future
NASH CRN patients as read by a pathol-
ogist serving each clinic rather than the
central consensus reading at the histol-
ogy reading center for the NASH CRN.
The model for advanced fibrosis was ex-
ternally validated using a cohort of NASH
CRN patients not included in the primary
analysis. This validation cohort consisted
of 100 patients from the same studies
and time period as used for the model
development based upon central review
of cases. The results remained statistically
significant and robust and consistent with
the model development cohort. One lim-
itation of the study is the recruitment of
patients from tertiary care centers. The
associations between diabetes-related
phenotypesddiabetes or diabetes-
related treatments, such as, but not
exclusively, insulin, metformin, sulfo-
nylureas, or statins and fibrates and
the duration of diabetesdand their
possible effects on the development
of NASH and advanced fibrosis were
not examined. This study population
may not represent the spectrum of pa-
tients in the general population seen in
primary care. Further studies would
be needed to externally validate these
results.
Implications for Future Research and
Clinical Practice
This study may help to guide further re-
search on potential relationships be-
tween NASH and diabetes. It may help
identify high-risk patients and target
interventions in order to prevent pro-
gression of NASH to cirrhosis and he-
patocellular carcinoma, especially in
populations with diabetes.
Currently, NAFLD Practice Guidelines
recommend the use of theNAFLD Fibrosis
Score for the screening for advanced fi-
brosis. In this report, we demonstrate
that the proposed model is better than
NAFLD Fibrosis Score in assessing ad-
vanced fibrosis in patients with diabetes.
If validated in an independent cohort, the
current model will replace the NAFLD fi-
brosis score in the NAFLD Practice Guide-
lines in future. These data could also be
used to screenpatientswith diabeteswho
should be screened for NASH prior to
Table 3—Clinical model for advanced fibrosis in adult patients with diabetes and
NAFLD
Characteristics (n = 346)
Clinical model*
OR 95% CI P
Demographics
Age (years) 1.04 1.01–1.07 0.007
Hispanic versus non-Hispanic 0.46 0.16–1.27 0.13
Clinical status
Hypertension 1.56 0.89–2.73 0.12
Obesity measures
BMI (kg/m2) 1.04 0.998–1.090 0.06
Waist-to-hip ratio 21.2 0.55–821 0.10
Laboratory measures
AST-to-ALT ratio 3.54 1.27–9.88 0.02
Alkaline phosphatase (units/L) 1.014 1.005–1.024 0.003
Isolated abnormal alkaline phosphatase 0.26 0.05–1.35 0.11
Globulin (g/dL) 2.27 1.26–4.07 0.006
Albumin (g/dL) 3.42 1.44–8.10 0.005
Total bilirubin (mg/dL) 0.44 0.16–1.24 0.12
Direct bilirubin (mg/dL) 24.4 0.47–1.254 0.11
INR 4.74 0.96–23.5 0.06
Hematology and other laboratory studies
Hematocrit (%) 0.902 0.83–0.98 0.01
Platelet count (1,000/mm3) 0.987 0.982–0.991 ,0.001
Serum insulin (mU/mL) 1.013 1.002–1.024 0.02
Model performance
Cross-validated AUROC 0.803 0.756–0.850
PPV 80.2%
NPV 75.1%
Correctly classified 76.6%
Sensitivity 57.0%
Specificity (fixed at 90%) 90.0%
AIC 368.4
Probability cutoff for advanced fibrosis† $0.60
Clinical model for P (probability of advanced fibrosis). Coefficients and SEs shown as b(se): log(P/
1 2 P) = 211.8(3.8) + 0.04(0.015) 3 age (years) + 0.042(0.023) 3 BMI (kg/m2) + 3.05(1.87) 3
waist-to-hip ratio + 0.014(0.005)3 ALK (units/L) + 1.26(0.52)3 AST-to-ALT ratio + 1.23(0.44)3
albumin (g/dL) + 0.82(0.30) 3 globulin (g/dL) 2 0.103(0.041) 3 hematocrit (%) 2 0.0133
(0.0024) 3 platelet count (1,000/mm3) + 3.19(2.01) 3 direct bilirubin (mg/dL) – 0.81(0.52) 3
total bilirubin (mg/dL) – 1.33(0.83) if abnormal alkaline phosphatase + 1.56(0.82)3 INR + 0.0131
(0.0056 3 serum insulin (mU/mL) 2 0.79(0.52) if Hispanic + 0.44(0.28) if hypertensive. ALK:
alkaline phosphatase; PPV: probability that the disease is present when the test is positive; NPV:
probability that the disease is not present when the test is negative. *Logistic regression model
variables selected from candidate set of baseline variables using AIC with backward selection to
select the model with the highest information from a large candidate set of baseline variables to
identify the predictors of advanced fibrosis in adult patients with diabetes with NAFLD: age, sex,
white race, Hispanic, hypertension, metabolic syndrome, abnormal alkaline phosphatase, BMI,
waist (cm), waist-to-hip ratio, AST, ALT, AST-to-ALT ratio, alkaline phosphatase, albumin, direct
bilirubin, total bilirubin, white blood cell count, platelets, GGT, total cholesterol, HDL, LDL,
triglycerides, ferritin, INR, serum glucose, serum insulin, globulin, hematocrit, HbA1c, and
HOMA-IR. †Classify as advanced fibrosis if the model probability of advanced fibrosis is $0.60.
This cutoff was chosen to give a specificity of 0.90.
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enrollment in a clinical trial. This is emerg-
ing to be an important unmet need, and
these findings provide a clinically useful
tool that can be applied directly in clini-
cal practice using routinely available
data.
Conclusion
Using a large, diverse cohort of patients
with biopsy-proven NAFLD and diabe-
tes, we developed a clinical prediction
guide to identify patients with diabetes
at risk for having NASH using readily
available clinical data such as BMI, pres-
ence of hypertension, and routine labo-
ratory values. This guide could potentially
impact an estimated 10million people re-
siding in the U.S. who have coexisting di-
abetes and NASH by allowing for early
identification of high-risk patients. These
models may help inform the decision as
to who should be considered for liver bi-
opsy and/or referred to a hepatologist for
further evaluation of NAFLD. Further
studies using additional biomarkers are
needed to improve the clinical models
and to better understand the pathogene-
sis of NASH and its relationship with di-
abetes.
Funding. This work was supported in part by
the American Gastroenterological Association
(AGA) Foundation–Sucampo–Association of
Specialty Professors (ASP) Designated Re-
search Award in Geriatric Gastroenterology
and by a T. Franklin Williams Scholarship
Award. Funding was also provided by The Atlantic
Philanthropies, the John A. Hartford Foundation,
the ASP, the AGA (to R.L.), and theNIDDK, National
Institutes of Health (grant K23-DK-090303). This
research was funded in part with the support of
the University of California, San Diego, Digestive
Table 4—Application of clinical models for NASH and advanced fibrosis in patients with diabetes and NAFLD
NASH clinical model
Probabilities of NASH
Total
Not NASH
(P , 0.33)
Gray zone
(0.33 # P # 0.75)
NASH
(P . 0.75)
Total patients 30 153 163 346
NASH present
Yes 7 85 149 241
No 23 68 14 105
Potential for biopsies spared by
application of the model 8.7% (30/346) 47.1% (163/346) 55.8% (193/346)
Advanced fibrosis clinical model
Probabilities of advanced fibrosis
Not advanced
fibrosis (P , 0.023)
Gray zone
(0.023 # P # 0.85)
Advanced fibrosis
(P . 0.85) Total
Total patients 10 300 36 346
Advanced fibrosis present
Yes 0 108 34 142
No 10 5,192 2 204
Potential for biopsies spared by
application of the model 2.9% (10/346) 10.4% (36/346) 13.3% (46/346)
Data are n unless otherwise indicated. The model probability cutoff of 0.75 for NASH and the probability cutoff of 0.85 for advanced fibrosis were
selected to attain a PPV of 90%. Application rule for NASH: do not biopsy if the probability of NASH is.0.75 (assume NASH) or,0.33 (assume not
NASH). Application rule for advanced fibrosis: do not biopsy if the probability of advanced fibrosis is .0.85 (assume advanced fibrosis) or ,0.023
(assume not advanced fibrosis). Note: the performance of these models varies with the prevalence of NASH (70%) and the prevalence of advanced
fibrosis (41%) in the population.
Table 5—Validation of clinical models for NASH and for advanced fibrosis in
external population
NASH
PModel development cohort Model validation cohort*
Number of patients 346 100
AUROC (95% CI) 0.82 (0.77–0.87) 0.83 (0.75–0.92) 0.76
PPV 93.4% 90.9% 0.39
NPV 43.8% 47.8% 0.48
Sensitivity 90.3% 91.4% 0.74
Specificity 54.7% 46.2% 0.13
Correctly classified 64.7% 62.0% 0.62
Prevalence 70% 65% 0.34
Advanced fibrosis
Model development cohort Model validation cohort* P
Number of patients 346 100
AUROC (95% CI) 0.84 (0.80–0.88) 0.84 (0.76–0.92) 0.97
PPV 80.2% 74.2% 0.20
NPV 75.1% 78.3% 0.51
Sensitivity 57.0% 60.5% 0.53
Specificity 90.0% 87.1% 0.41
Correctly classified 76.6% 77.0% 0.93
Prevalence 41% 38% 0.59
*The validation data set consists of data from future NASH CRN patients as read by a pathologist
serving each clinic rather than the central, consensus reading at the histology reading center for
the NASH CRN. These patients were not included in the primary analysis. This validation cohort
consists of 100 patients from the same studies and time period as used for the model
development based upon central review of cases.
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